Are we looking at the same company? I’d hardly call this under...

Are we looking at the same company? I’d hardly call this under valued. They missed their prospectus forecast by a huge margin in year 1 and destroyed all credibility, they’re a roll up that are buying dentist practices at 5.5x which is higher than their present EV/EBITDA multiple, which is value destroying and they’re the last player to the dentistry roll up game so all the low hanging fruit is gone. 

Cheap doesn’t mean good. I’d avoid for now until they can deliver on promises